Has anyone ever considered how the fight against cancer begins? Here at The Early Cancer Institute in Cambridge, that very question is at the heart of everything. The Early Cancer Institute isn’t just another research facility. It’s the UK’s first institute solely dedicated to the early detection of cancer, a beacon of hope on the Cambridge Biomedical Campus. Opened in 2022, The Early Cancer Institute is determined to transform the narrative around cancer. Its mission is to detect cancer early enough to cure it. Professor Rebecca Fitzgerald, the director, champions this mission. She points out the historical neglect of early cancer research in favor of treatments for later stages. The institute is tackling this head-on.
The Early Cancer Institute focuses on cancers known for their devastatingly low survival rates: lung, pancreatic, esophageal, liver cancers, and acute myeloid leukemia. The institute’s multidisciplinary team includes biologists, clinicians, engineers, physicists, and social scientists. They collaborate under one roof, driven by a shared purpose. Their goal is to unravel the mysteries of cancer development and evolution. This knowledge is then used to create groundbreaking methods for detection, treatment, and even prevention. The location of The Early Cancer Institute within the Cambridge Biomedical Campus is no accident. This proximity to world-leading academic, NHS, and industrial partners is crucial for its success. Partners include the Cancer Research UK Cambridge Institute, the Stem Cell Institute, and pharmaceutical giants AstraZeneca and GSK.
One remarkable success story from The Early Cancer Institute involves the Cytosponge. Developed by Professor Fitzgerald, this simple yet effective “pill on a string” test helps determine whether heartburn patients have Barrett’s esophagus, a precursor to esophageal cancer. The institute also houses researchers like Professor Serena Nik-Zainal, a “DNA detective.” She uses whole genome sequencing to analyze tumor DNA. By identifying “mutational signatures,” she can trace the origins of cancer. Dr. Jamie Blundell, an evolutionary biologist, studies blood samples from patients with blood cancers. These samples, taken years before diagnosis, serve as a “fossil record.” They allow him to track the earliest signs of cancer development. Dr. Matt Hoare focuses on primary liver cancer, a rising concern in the UK. He emphasizes the need for earlier detection and the potential of genome sequencing in understanding this cancer.
The Early Cancer Institute is not just researching; it’s building a future where cancer is no longer a source of fear. A generous £11 million donation allowed for the redevelopment of the Hutchison building. Now renamed the Li Ka Shing Early Cancer Institute, it stands as a testament to the dedication and hope driving the fight against cancer. The institute’s vision is bold: a world where people no longer fear cancer. And right here, at The Early Cancer Institute, that vision is becoming a reality.